Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;33(12):1328-1331.
doi: 10.1016/j.annonc.2022.08.089. Epub 2022 Sep 17.

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle  1 , F Peyraud  2 , L Belcaid  3 , M Brunet  4 , M Aldea  5 , R Clodion  6 , P Dubos  4 , D Vasseur  7 , C Nicotra  6 , A Geraud  6 , M Sakkal  6 , L Cerbone  8 , F Blanc-Durand  8 , F Mosele  8 , P Martin Romano  6 , M Ngo Camus  6 , I Soubeyran  9 , E Khalifa  9 , M Alame  9 , L Blouin  9 , D Dinart  10 , C Bellera  10 , A Hollebecque  6 , S Ponce  6 , Y Loriot  6 , B Besse  5 , L Lacroix  7 , E Rouleau  7 , F Barlesi  11 , F Andre  5 , A Italiano  12
Affiliations
Free article

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle et al. Ann Oncol. 2022 Dec.
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure AlI received research grants from AstraZeneca, Bayer, Bristol Myers Squibb (BMS), Chugai, Merck, Merck Sharp & Dohme (MSD), Pharmamar, Novartis, Roche, and received personal fees from Epizyme, Bayer, Lilly, Roche, and Springworks. BB received grants from AstraZeneca, Pfizer, Eli Lilly, Onxeo, BMS, Inivata, AbbVie, Amgen, Blueprint Medicines, Celgene, GlaxoSmithKline (GSK), Ignyta, Ipsen, Merck KGaA, MSD Oncology, Nektar, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Therapeutics, Cristal Therapeutics, Daiichi Sankyo, Janssen Oncology, OSE Immunotherapeutics, BeiGene, Boehringer Ingelheim, Genentech, Servier, and Tolero Pharmaceuticals. FB has received consultancy fees from AstraZeneca, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, and Takeda. All other authors have declared no conflicts of interest.

Publication types